FDA Announces Public Hearing to Establish Criteria for Psychedelic Therapies to Enter the Regulatory Framework
Accelerating the Federal Government's Integration of Psychedelic Therapies
The U.S. Food and Drug Administration (FDA) announced a public hearing on September 14, 2026, to discuss the future therapeutic use of psychedelic drugs. This hearing is part of the Biden administration's Executive Order 14401, 'Accelerating Treatments for Serious Mental Illness,' and follows the July 2026 release of the final guidance 'Psychedelic Drugs: Considerations for Clinical Investigations.' Rather than being a one-time event, the hearing is designed to establish concrete criteria across four key areas: provider education, patient safety protocols, patient access, and data standardization. The federal government aims to proactively align regulatory guidelines to ensure that innovative substances previously classified as controlled substances can transition smoothly into mainstream therapeutic use.
Addressing Unmet Medical Needs and Shaping a Major Market
This initiative could offer new treatment options for patients with treatment-resistant mental disorders such as depression, post-traumatic stress disorder (PTSD), and generalized anxiety disorder (GAD), who have not responded to conventional antidepressants. The global psychedelic therapy market is estimated to be between $260 million and $702 million in 2025, with a high compound annual growth rate (CAGR) of 12% to 17%, projected to expand to as much as $12.9 billion by 2034–2035. Given the anticipated explosive market growth, it is essential for regulatory agencies to establish safe dosing environments and monitoring standards in advance to facilitate post-commercialization reimbursement and widespread prescription.
Leading Candidates Advancing to Phase 3 Trials and Regulatory Re-Submissions
Current market attention is focused on companies with pipeline candidates in Phase 3 trials. Compass Pathways (CMPS) is conducting Phase 3 trials (COMP005 and COMP006) of COMP360 (psilocybin) for treatment-resistant depression (TRD), while MindMed (MNMD) is advancing MM120 (LSD D-tartrate) for generalized anxiety disorder. Lykos Therapeutics, which received a Complete Response Letter (CRL) in August 2024, rebranded as Resilient Pharmaceuticals and submitted a revised New Drug Application (NDA) in August 2026, bypassing additional Phase 3 trials by addressing cardiac safety data and protocol violations.
Overcoming Functional Unblinding and Standardizing Oversight
The biggest challenges in psychedelic drug development include functional unblinding, where patients can intuitively detect whether they have received the drug, and the risk of misuse. The public hearing will focus on the implementation of supervised setting protocols, where trained professionals administer the drug in specialized treatment centers, and the standardization of long-term tracking data. Establishing these regulatory standards will allow companies to predict approval criteria from the clinical design stage, reducing risk, and enabling institutional investors to allocate capital with reduced regulatory uncertainty, thereby improving overall investment sentiment in the biopharma sector.
This public hearing is a key indicator of the pace at which the global psychedelic therapy market, projected to reach up to $7.02 billion in 2025 and grow at 12–17% annually to $12.9 billion by 2035, will integrate into the regulatory framework. In the short term, it is expected to directly influence the regulatory review of Resilient Pharmaceuticals' Rysanso (MDMA), for which a revised NDA was submitted in August 2026. In the medium to long term, it will serve as a pivotal moment in determining the commercial approval prospects, pricing models, and insurance reimbursement criteria for follow-on pipeline candidates such as Compass Pathways' COMP360 (psilocybin) and MindMed's MM120 (LSD D-tartrate). From the perspective of researchers and medical institutions, the hearing is also expected to clarify provider qualification requirements and standard clinical data collection guidelines for establishing supervised treatment environments, which will help overcome the major development hurdle of functional unblinding risk.